Insider Selling: NantHealth Inc (NH) COO Sells 6,175 Shares of Stock

NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 6,175 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $3.52, for a total value of $21,736.00. Following the transaction, the chief operating officer now owns 89,690 shares of the company’s stock, valued at $315,708.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ronald Allen Louks also recently made the following trade(s):

  • On Wednesday, December 6th, Ronald Allen Louks sold 5,245 shares of NantHealth stock. The stock was sold at an average price of $3.03, for a total value of $15,892.35.
  • On Monday, November 6th, Ronald Allen Louks sold 6,705 shares of NantHealth stock. The stock was sold at an average price of $3.39, for a total value of $22,729.95.

NantHealth Inc (NH) opened at $3.95 on Wednesday. The stock has a market capitalization of $408.40, a PE ratio of -2.22 and a beta of -1.50. NantHealth Inc has a 1-year low of $2.60 and a 1-year high of $10.02. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93.

NantHealth (NASDAQ:NH) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The business had revenue of $21.76 million for the quarter, compared to analysts’ expectations of $29.42 million. During the same quarter last year, the business earned ($0.18) earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. equities analysts forecast that NantHealth Inc will post -1.35 EPS for the current year.

Several analysts have recently commented on NH shares. Jefferies Group restated a “buy” rating and set a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. Zacks Investment Research upgraded NantHealth from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Thursday, October 12th. BidaskClub cut NantHealth from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Finally, Canaccord Genuity decreased their target price on NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $8.05.

Institutional investors and hedge funds have recently modified their holdings of the business. Alliancebernstein L.P. acquired a new stake in shares of NantHealth during the second quarter worth about $102,000. GSA Capital Partners LLP acquired a new stake in shares of NantHealth during the second quarter worth about $121,000. Teachers Advisors LLC raised its position in shares of NantHealth by 351.8% during the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after purchasing an additional 24,588 shares during the period. California State Teachers Retirement System raised its position in shares of NantHealth by 132.4% during the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after purchasing an additional 18,000 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of NantHealth during the third quarter worth about $180,000. Hedge funds and other institutional investors own 7.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/nanthealth-inc-nh-coo-ronald-allen-louks-sells-6175-shares-of-stock/1822449.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.